The Food and Drug Administration on Wednesday approved the first gene therapy treatment for cancer, green-lighting Novartis Pharmaceuticals’ cell therapy treatment for childhood leukemia. The regulatory approval had been widely expected but came earlier than analysts’ predictions. It signals that other drug companies developing cell-therapy treatments may also be able to commercialize what medical experts say is a revolutionary new form of medicine. The therapy extracts a patient’s cells from his or her blood, sends them to a manufacturing site to genetically modify them, and then re-infuses them into the person’s body to attack cancer cells.
NYS Entity Status
NYS Filing Date
JULY 17, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - BLOOD CELL TECHNOLOGIES, LLC
AROUND THE WEB
- FDA approves 1st gene therapy treatment for cancer
By Catherine Ho - Wednesday Aug 30, 2017
- Health thyself: Skin-zapping chip aims to reprogram cells for tissue repair
By Beth Mole - Thursday Aug 10, 2017
With an electrical pulse, skin cells form blood vessels and neurons in early animal work.
- Rubius Adds $120M to Ready Tests of Red Blood Cells as Drug Carriers
By Frank Vinluan - Wednesday Jun 21, 2017
The main role of red blood cells is to carry life-sustaining oxygen throughout the body. Rubius Therapeutics believes these cells can carry something more: therapeutic payloads delivered directly to the organs and tissues of patients with severe diseases. Less than two years after launch, Cambridge, MA-based Rubius has reeled in $120 million in funding from […]
- WD Navarre Holdings Files for Chapter 11 Protection
Friday Sep 8, 2017
WD Navarre Holdings LLC, the corporate parent of technology products distributor WYNIT Distribution LLC, filed for bankruptcy protection Friday.
- Harvard Biotech Spinout Lands $10M to Make Platelets From Stem Cells
By Frank Vinluan - Thursday Jun 8, 2017
If you’ve donated blood, you probably received a follow-up message asking you to consider a platelet donation. Donation centers must constantly replenish their blood supplies, but the need for platelets is particularly acute. Compared to other components of blood, platelets are fragile and short lived, which puts high demand on the small supply of these […]
- US clears first ‘living drug’ for tough childhood leukemia
By Associated Press - Wednesday Aug 30, 2017
WASHINGTON — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis and the University of Pennsylvania is the first type of...